Kite Pharma, Inc. (NASDAQ:KITE) EVP Helen Susan Kim sold 26,649 shares of the stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $109.28, for a total value of $2,912,202.72. Following the completion of the transaction, the executive vice president now owns 28,763 shares in the company, valued at approximately $3,143,220.64. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Helen Susan Kim also recently made the following trade(s):
- On Thursday, August 10th, Helen Susan Kim sold 6,251 shares of Kite Pharma stock. The shares were sold at an average price of $120.09, for a total value of $750,682.59.
- On Tuesday, August 8th, Helen Susan Kim sold 79,949 shares of Kite Pharma stock. The shares were sold at an average price of $119.56, for a total value of $9,558,702.44.
Shares of Kite Pharma, Inc. (KITE) traded up 3.29% during midday trading on Friday, hitting $130.18. The stock had a trading volume of 1,058,415 shares. The firm’s market cap is $7.44 billion. Kite Pharma, Inc. has a 12-month low of $39.82 and a 12-month high of $130.64. The company’s 50-day moving average price is $111.51 and its 200-day moving average price is $84.63.
Kite Pharma (NASDAQ:KITE) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.97) by $0.03. Kite Pharma had a negative net margin of 1,117.44% and a negative return on equity of 59.56%. The business had revenue of $10.10 million for the quarter, compared to analyst estimates of $9.59 million. During the same quarter in the prior year, the business earned ($0.91) EPS. Kite Pharma’s quarterly revenue was up 110.4% on a year-over-year basis. Equities research analysts forecast that Kite Pharma, Inc. will post ($8.19) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/08/19/helen-susan-kim-sells-26649-shares-of-kite-pharma-inc-nasdaqkite-stock-updated-updated.html.
Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of Kite Pharma by 106,272.1% in the first quarter. BlackRock Inc. now owns 3,621,971 shares of the biopharmaceutical company’s stock worth $284,287,000 after buying an additional 3,618,566 shares during the period. TD Asset Management Inc. increased its stake in shares of Kite Pharma by 148.7% in the first quarter. TD Asset Management Inc. now owns 61,550 shares of the biopharmaceutical company’s stock worth $4,831,000 after buying an additional 36,800 shares during the period. Russell Investments Group Ltd. purchased a new stake in shares of Kite Pharma during the fourth quarter worth $801,000. Great West Life Assurance Co. Can increased its stake in shares of Kite Pharma by 28.1% in the first quarter. Great West Life Assurance Co. Can now owns 5,013 shares of the biopharmaceutical company’s stock worth $392,000 after buying an additional 1,100 shares during the period. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Kite Pharma during the first quarter worth $282,000. Hedge funds and other institutional investors own 83.94% of the company’s stock.
Several analysts have recently commented on KITE shares. UBS AG cut Kite Pharma from an “outperform” rating to a “market perform” rating in a report on Monday, May 8th. Canaccord Genuity set a $120.00 price target on Kite Pharma and gave the company a “buy” rating in a report on Wednesday, August 9th. Jefferies Group LLC reissued a “buy” rating and issued a $135.00 price target (up from $121.00) on shares of Kite Pharma in a report on Wednesday, August 9th. Stifel Nicolaus reissued a “hold” rating and issued a $74.00 price target on shares of Kite Pharma in a report on Thursday, August 10th. Finally, Vetr cut Kite Pharma from a “buy” rating to a “hold” rating and set a $116.82 price target for the company. in a report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $88.93.
Kite Pharma Company Profile
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
What are top analysts saying about Kite Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Kite Pharma Inc. and related companies.